Daklataswir
| |||||||||||
| |||||||||||
| Ogólne informacje | |||||||||||
| Wzór sumaryczny |
C40H50N8O6 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Masa molowa |
738,89 g/mol | ||||||||||
| Identyfikacja | |||||||||||
| Numer CAS | |||||||||||
| PubChem | |||||||||||
| DrugBank | |||||||||||
| |||||||||||
| |||||||||||
| |||||||||||
| Klasyfikacja medyczna | |||||||||||
| ATC | |||||||||||
Daklataswir – organiczny związek chemiczny, lek przeciwwirusowy skierowany przeciwko wirusowi C zapalenia wątroby, lek hamuje produkcję białka HCV NS5A, jest pierwszym lekiem w swojej klasie. Zatwierdzony przez komisję Europejską 22 sierpnia 2014[1].
Badania kliniczne
[edytuj | edytuj kod]- Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01471574 (ang.).
- A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01497834 (ang.).
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01581203 (ang.).
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01573351 (ang.).
- Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients (COMMAND-3), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01492426 (ang.).
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01425970 (ang.).
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01616524 (ang.).
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01492504 (ang.).
Przypisy
[edytuj | edytuj kod]- ↑ Daclatasvir to treat chronic hepatitis C. pharmaworldmagazine.com, 2014-10-21. [dostęp 2015-02-22].
Bibliografia
[edytuj | edytuj kod]- F. Suzuki, H. Sezaki, N. Akuta, Y. Suzuki i inni. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. „J Clin Virol”, Jun 2012. DOI: 10.1016/j.jcv.2012.04.024. PMID: 22658798.
- Z. Plaza, V. Soriano, E. Vispo, M. Del Mar Gonzalez i inni. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. „Antivir Ther”, Mar 2012. DOI: 10.3851/IMP2091. PMID: 22436385.
- C. Wang, H. Huang, L. Valera, J.H. Sun i inni. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. „Antimicrob Agents Chemother”. 56 (3), s. 1350–1358, Mar 2012. DOI: 10.1128/AAC.05977-11. PMID: 22214777.
- C. Wang, L. Jia, H. Huang, D. Qiu i inni. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. „Antimicrob Agents Chemother”. 56 (3), s. 1588–1590, Mar 2012. DOI: 10.1128/AAC.06169-11. PMID: 22203595.
- D. Dieterich. The end of the beginning for hepatitis C treatment. „Hepatology”. 55 (3), s. 664–665, Mar 2012. DOI: 10.1002/hep.25528. PMID: 22174100.
